These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35834597)

  • 1. Investigating the Effects of a Synthetic Cannabinoid on the Pathogenesis of Leukemia and Leukemic Stem Cells: A New Therapeutic Approach.
    Salcin H; Goker Bagca B; Alcitepe I; Biray Avci C; Aslan R; Annette Akgur S; Tezcanli Kaymaz B
    Cannabis Cannabinoid Res; 2024 Feb; 9(1):212-222. PubMed ID: 35834597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model.
    Yin Z; Su R; Ge L; Wang X; Yang J; Huang G; Li C; Liu Y; Zhang K; Deng L; Fei J
    Int J Biol Sci; 2023; 19(4):1211-1227. PubMed ID: 36923939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
    Li H; Liu L; Zhuang J; Liu C; Zhou C; Yang J; Gao C; Liu G; Sun C
    Mol Genet Genomic Med; 2019 Sep; 7(9):e851. PubMed ID: 31373443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
    Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
    Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
    Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.
    Avilés-Vázquez S; Chávez-González A; Hidalgo-Miranda A; Moreno-Lorenzana D; Arriaga-Pizano L; Sandoval-Esquivel MÁ; Ayala-Sánchez M; Aguilar R; Alfaro-Ruiz L; Mayani H
    Cancer Med; 2017 Dec; 6(12):2942-2956. PubMed ID: 29030909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
    Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
    Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
    Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
    Zhang B; Li L; Ho Y; Li M; Marcucci G; Tong W; Bhatia R
    J Clin Invest; 2016 Mar; 126(3):975-91. PubMed ID: 26878174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
    Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
    Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
    Mojtahedi H; Yazdanpanah N; Rezaei N
    Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthetic cannabinoid JWH-018 modulates Saccharomyces cerevisiae energetic metabolism.
    Ferreira C; Couceiro J; Família C; Jardim C; Antas P; Santos CN; Outeiro TF; Tenreiro S; Quintas A
    FEMS Yeast Res; 2019 Aug; 19(5):. PubMed ID: 31329229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
    Muselli F; Peyron JF; Mary D
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.
    Zhang H; Peng C; Hu Y; Li H; Sheng Z; Chen Y; Sullivan C; Cerny J; Hutchinson L; Higgins A; Miron P; Zhang X; Brehm MA; Li D; Green MR; Li S
    Nat Genet; 2012 Jul; 44(8):861-71. PubMed ID: 22797726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic cannabinoids JWH-018, JWH-122, UR-144 and the phytocannabinoid THC activate apoptosis in placental cells.
    Almada M; Alves P; Fonseca BM; Carvalho F; Queirós CR; Gaspar H; Amaral C; Teixeira NA; Correia-da-Silva G
    Toxicol Lett; 2020 Feb; 319():129-137. PubMed ID: 31730886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells.
    Sullivan C; Chen Y; Shan Y; Hu Y; Peng C; Zhang H; Kong L; Li S
    PLoS One; 2011; 6(10):e26246. PubMed ID: 22039451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
    Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
    Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
    Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
    Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
    Willmann M; Sadovnik I; Eisenwort G; Entner M; Bernthaler T; Stefanzl G; Hadzijusufovic E; Berger D; Herrmann H; Hoermann G; Valent P; Rülicke T
    Exp Hematol; 2018 Jan; 57():50-59.e6. PubMed ID: 29031704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
    Hu Y; Chen Y; Douglas L; Li S
    Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.